These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 19375623)
1. Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Fleshner NE; Lawrentschuk N Urology; 2009 May; 73(5 Suppl):S21-7. PubMed ID: 19375623 [TBL] [Abstract][Full Text] [Related]
2. New circulating biomarkers for prostate cancer. Bensalah K; Lotan Y; Karam JA; Shariat SF Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918 [TBL] [Abstract][Full Text] [Related]
3. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878 [TBL] [Abstract][Full Text] [Related]
4. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715 [TBL] [Abstract][Full Text] [Related]
5. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725 [TBL] [Abstract][Full Text] [Related]
6. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597 [TBL] [Abstract][Full Text] [Related]
7. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project. Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118 [TBL] [Abstract][Full Text] [Related]
8. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Pienta KJ Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622 [TBL] [Abstract][Full Text] [Related]
9. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213 [TBL] [Abstract][Full Text] [Related]
11. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070 [TBL] [Abstract][Full Text] [Related]
13. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157 [TBL] [Abstract][Full Text] [Related]
14. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Connolly D; Black A; Gavin A; Keane PF; Murray LJ Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343 [TBL] [Abstract][Full Text] [Related]
15. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. Schröder FH; Roobol MJ; Andriole GL; Fleshner N J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915 [TBL] [Abstract][Full Text] [Related]
16. A framework for the identification of men at increased risk for prostate cancer. Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies. Rydén L; Egevad L; Ekman P; Hellström M Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221 [TBL] [Abstract][Full Text] [Related]
18. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
19. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]. Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478 [TBL] [Abstract][Full Text] [Related]
20. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]